





# Bhutan

South-East Asia Region



## I. Epidemiological profile


Population (UN)	2016	%	Parasites and vectors
Number of active foci	7		Plasmodium species: <i>P. falciparum</i> (13%), <i>P. vivax</i> (87%)
Number of people living within active foci	31,500	4	Major anopheles species: <i>An. culicifacies</i> , <i>An. maculatus</i> , <i>An. philippinensis</i> , <i>An. annularis</i>
Malaria-free (0 cases)	766,000	96	Reported confirmed cases (health facility): 15
Total	797,800		Confirmed cases at community level: -
			Reported deaths: 0

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2006	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2006	First-line treatment of <i>P. falciparum</i>	AL	2006					
IRS	IRS is recommended	Yes	1964	Treatment failure of <i>P. falciparum</i>	QN	2006					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AM; QN	2006					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2006					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2006	Type of RDT used		P.f + P.v specific (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	1964								
Treatment	ACT is free of charge for all ages in public sector	Yes	2006	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2012	AL	2010-2013	0	0	0	28 days	4	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-	CQ	2013-2015	0	0	0	28 days	1	<i>P. vivax</i>
	G6PD test is a requirement before treatment with primaquine	No	-	CQ+PQ	2010-2013	0	0	0	28 days	4	<i>P. vivax</i>
	Directly observed treatment with primaquine is undertaken	No	-	<b>Insecticide resistance tests (mosquito mortality, %)</b>							
	System for monitoring adverse reactions to antimalarials exists	Yes	2012	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
Surveillance	ACD for case investigation (reactive)	Yes	2013	Pyrethroids	2010-2012	1	1	1	2	<i>An. pseudowillmori</i>	
	ACD of febrile cases at community level (pro-active)	Yes	2014								
	Mass screening is undertaken	Yes	2014								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	2012								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	Yes	2012								
Case reporting from private sector is mandatory	Yes	2015									

## III. Financing

Sources of financing




Government expenditure by intervention in 2016




## IV. Coverage


Coverage of ITN and IRS




Cases tested



Cases treated




Cases tracked




## V. Impact

Confirmed malaria cases per 1000 and ABER



Number of malaria cases



**Notes:**  
Reported confirmed cases and reported deaths are indigenous only